雄激素受体与三阴性乳腺癌相关研究现状  

Research Progress in Androgen Receptor and Triple Negative Breast Cancer

作　　者：贾闵羽 JIA Minyu(Department of Palliative Medicine,West China Fourth Hospital of Sichuan University,Chengdu 610000,China)

机构地区：[1]四川大学华西第四医院姑息医学科,成都610000

出　　处：《中国医学科学院学报》2023年第2期303-310,共8页Acta Academiae Medicinae Sinicae

摘　　要：在乳腺癌的研究中,尽管雄激素受体(AR)在三阴性乳腺癌(TNBC)中的预后价值存在争议,但已有研究表明,缺乏AR表达会加剧疾病进展。并且在TNBC亚型中,与AR(+)TNBC相比,AR(-)TNBC会因缺乏预后生物标志物和治疗靶点更具侵袭性。随着磷脂酰肌醇3-激酶/蛋白激酶B、S期激酶相关蛋白2信号通路等新型治疗靶点以及新兴免疫疗法的深入研究,TNBC的治疗可选择方案也在不断增加。关于AR在TNBC中的作用机制,目前AR(-)TNBC肿瘤生物学的研究和新的生物标志物的文献仍然很少。本文总结了AR在TNBC中的研究现状,提出了TNBC未来研究的途径、潜在生物标志物和治疗策略。The research on androgen receptor(AR)in breast cancer is advancing.Although the prognostic value of AR in triple negative breast cancer(TNBC)is controversial,a variety of studies have demonstrated that the lack of AR expression exacerbates disease progression.Moreover,the TNBC subtype of AR(-)is more aggressive than that of AR(+)due to the lack of prognostic biomarkers and therapeutic targets.With the discovery and deepening research of novel therapeutic targets such as phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin and S-phase kinase-associated protein 2 signaling pathways,as well as the emerging of immunotherapies,the treatment options for TNBC are increasing.Regarding the role of AR in TNBC,the studies about the tumor biology of AR(-)TNBC and novel biomarkers for improved management of the disease remain insufficient.In this review,we summarize the research progress of AR in TNBC,put forward avenues for future research on TNBC,and propose potential biomarkers and therapeutic strategies that warrant investigation.

关 键 词：三阴性乳腺癌 雄激素受体 雄激素受体拮抗剂 肿瘤生物标志物 

分 类 号：R737.9[医药卫生—肿瘤]